Happinet sharply raises operating profit forecast from 7.8 billion to 13.5 billion yen; Chugai Pharmaceutical hits year-to-date low after Roche halts obesity development

ダイヤモンド・ザイ··JPCH·Read original
3▲1 ▼2Impact / 5
Summary · why it matters

Happinet has sharply raised its operating profit forecast for the first half of the fiscal year ending March 2027, from 7.8 billion yen to 13.5 billion yen. That marks a 55.0 percent increase from the same period a year earlier, driven by strong performance in lottery products for convenience stores and trading cards in its toy business, as well as capsule toys in its amusement business. Meanwhile, Chugai Pharmaceutical saw its share price fall to a year-to-date low of 6,096 yen after its strategic partner Roche of Switzerland announced it was halting development of the anti-latent myostatin-sweeping antibody emugrobart for obesity. Chugai Pharmaceutical is set to receive the return of the licensing rights from Roche. The Nikkei Stock Average extended its decline, closing at 65,481.27 yen, down 396.35 yen from the previous day.

Impact on assets 3

Biotech & Genomic Medicine▼
Chugai Pharmaceutical Co., Ltd.
4519
▼ NegativeTechnologyrelevance

Roche halted development of emugrobart for obesity, and Chugai gets the licensing rights returned, hitting its shares to a year-to-date low.

Consumer Discretionary▲
Happinet Corporation
7552
▲ PositiveCapitalrelevance

Happinet sharply raised its H1 operating profit forecast from 7.8bn to 13.5bn yen, a 55% YoY increase.

Health Care▼
Roche Holding AG
ROP
▼ NegativeTechnologyrelevance

Roche announced it is halting development of the anti-latent myostatin-sweeping antibody emugrobart for obesity.